Biogen maintained by Jefferies at hold

Biogen Idec Inc. was maintained by Jefferies & Co. analyst Adam Walsh at a hold rating with a price target on the stock of $39 per share following its supplementary biologics license application made with partner Elan Corp. plc for a revised label for their multiple sclerosis drug Tysabri. Biogen shares Tuesday were down $0.41, or 1.07%, at $38.05 on volume of 3,905,279 shares versus the three-month running average of 3,756,640 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.